Utskrift från Malmö universitets webbplats www.mah.se

Dermal Drug Delivery – How to increase bioavailability in viable skin?

Contact person: Johan Engblom
Responsible: Johan Engblom
Co-workers: Tautgirdas Ruzgas, Peter Falkman, Cathrine Albèr, Marija Jankunec, Enamul Mojumdar and Sara Thuresson
Partner: Bioglan AB, Galenica AB, Emeriti Pharma AB, Gothenburg University (Assoc. prof. M Ericson, Dr. Julia Fernandez-Rodriguez)
Funding: the Knowledge foundation (www.kks.se)
Timeframe: 2015-03-01 -- 2018-02-28
Forskningscentrum: Biofilms - Research Center for Biointerfaces
Faculty/Department: Faculty of Health and Society, The Department of Biomedical Science

Increase in skin permeability is a prerequisite for successful delivery of hydrophilic compounds, macromolecules and conventional drugs for new therapeutic indications. Though the primary barrier to percutaneous absorption lies within stratum corneum (typically 80%) diffusion within the viable tissue, metabolism and transport by interstitial fluid will also influence the bioavailability of compounds in specific skin compartments.

The aim of the current project is to gain further understanding on how to increase bioavailability of topically administered hydrophilic and hydrophobic API’s in viable epidermis and dermis. To address this rather complex question we will i) evaluate drug release from, and physicochemical properties of the residual film formed by three representative formulations (an ointment, a cream and a gel) at fixed ambient conditions, ii) investigate the potential of introducing a non-volatile co-solvent to increase the capacity of the stratum corneum reservoir, and iii) test whether topical co-administration of a vasoconstrictor can increase drug concentrations in stratum corneum, viable epidermis and dermis.

The proposed project is a collaboration between Emeriti Pharma AB, Galenica AB, Bioglan AB, Malmö University and Gothenburg University. The expected outcome from the project is joint publications, increased “industry/academia/academia” collaboration and increased know-how in relevant research fields for all partners. Emeriti Pharma is eager to learn more on how hydrophilic products are best formulated for topical use. Galenica on the other hand has a specific interest in topical delivery of steroids, which are rather lipophilic. The motivation for Bioglan to take part in this project is to strengthen their knowledge-base in the topical drug delivery field. This will make Bioglan more competent and competitive as more knowhow and technologies can be offered to their clients.

At Malmö University, research activities related to topical drug delivery and phenomena related to barrier perturbation and transport over biological membranes (such as skin, mucosa, nail and leaf) have grown within the frame of Biofilms – Research Center for Biointerfaces (BRCB). The current  project combines expertise from various disciplines within pharmaceutical industry and offers a an interesting possibility to further explore the potential of Two Photon Micorscopy. It would fit perfect into our portfolio and with the strategy to further develop the Mah-LU “Topical science Cluster” initiative from 2012. A closer collaboration with GU and Marica Ericsons Research Center “SkinResQU” would generate a strong hub in Southern Sweden for topical drug delivery and skin research.


Senast uppdaterad av Magnus Jando